UniProt Q08345 · PDB · AlphaFold · Substrate: IRS1tide · Clone: Catalytic (aa444-876)high-confidence target
Top inhibitors
| # | Drug | Inhibition | Residual | KISS | Gini |
|---|---|---|---|---|---|
| 1 | Cabozantinib | 100.0% | 0.0% | 92.73 | 0.751 |
| 2 | Dasatinib | 99.3% | 0.7% | 87.97 | 0.699 |
| 3 | Repotrectinib | 99.3% | 0.7% | 84.21 | 0.608 |
| 4 | Nilotinib | 98.5% | 1.5% | 96.49 | 0.765 |
| 5 | Vandetanib | 98.5% | 1.5% | 95.74 | 0.723 |
| 6 | Canertinib | 98.5% | 1.5% | 96.49 | 0.671 |
| 7 | Tivozanib | 97.1% | 2.9% | 92.42 | 0.673 |
| 8 | Ripretinib | 96.9% | 3.1% | 92.95 | 0.674 |
| 9 | Pralsetinib | 96.9% | 3.1% | 93.43 | 0.643 |
| 10 | Midostaurin | 96.2% | 3.8% | 78.64 | 0.500 |
| 11 | Nintedanib | 96.1% | 3.9% | 90.23 | 0.608 |
| 12 | Avapritinib | 96.0% | 4.0% | 97.73 | 0.644 |
| 13 | Entrectinib | 96.0% | 4.0% | 93.69 | 0.671 |
| 14 | Erdafitinib | 95.8% | 4.2% | 95.71 | 0.737 |
| 15 | Gilteritinib | 95.7% | 4.3% | 88.97 | 0.506 |
| 16 | Dacomitinib | 95.6% | 4.4% | 97.99 | 0.664 |
| 17 | Ponatinib | 95.3% | 4.7% | 78.23 | 0.534 |
| 18 | Fedratinib | 95.2% | 4.8% | 96.21 | 0.576 |
| 19 | Imatinib | 94.5% | 5.5% | 99.00 | 0.718 |
| 20 | Bosutinib | 94.3% | 5.7% | 87.22 | 0.555 |
Paralog block
No paralog group registered for this kinase.
EMT expression
- Mesenchymal log2(TPM+1): 4.89
- Epithelial log2(TPM+1): 5.96
- Fold change: -1.07
- Status: Downregulated
High-confidence drugs
- Imatinib — inh 94.5% · KISS 59.98
- Nilotinib — inh 98.5% · KISS 49.78
- Infigratinib — inh 91.7% · KISS 48.72
Selectivity landscape vs inhibition on DDR1
Each point is one of the 92 approved drugs; color = inhibition % on DDR1.
3D structure
Embedded NGL viewer pulls a representative PDB entry (or AlphaFold model if no experimental structure is registered). Heavy bundle — loaded only on demand.
Annotations
Sign in to read and post annotations.
Loading…